The short answer
Bitter melon may affect glucose, but a harmful interaction with glimepiride has not been demonstrated in the sources checked. Findings vary by product and study. Discuss supplement use with your diabetes clinician; neither blanket avoidance nor a protective spacing interval is established.
What this answer covers
Momordica charantia fruit preparations with oral glimepiride. Prediabetes studies without medicines and specified extracts are not equivalent to all seed, juice or food products.
- Supplement or preparation
- Bitter melon
- Medication ingredient
- glimepiride
A diabetes trial did not show a clear benefit
A small placebo-controlled capsule study in treated type 2 diabetes found no significant improvement in HbA1c or fasting glucose. The original abstract does not establish glimepiride co-use. This limits a blanket claim that the supplement necessarily adds substantial glucose lowering.
Positive findings came from a different setting
A trial of a specified unripe-fruit extract found changes in some glucose-challenge measures in people with prediabetes. It excluded medicines that affect glucose. Those findings cannot measure an interaction with glimepiride.
Food and extracts are not interchangeable
A culinary serving, juice and concentrated extract can provide different exposures. The preparation and other ingredients matter when reviewing the product. A study of one formulation cannot establish a safe amount for every bitter-melon supplement.
Coordinate changes and glucose monitoring
Because glimepiride itself can cause low blood sugar, discuss starting or stopping the supplement and unexpected readings with the prescriber. There is no demonstrated interval that removes possible overlapping glucose effects. Do not replace prescribed treatment with the supplement.
Evidence and practical considerations
Side effects & toxicity
Bitter melon may affect glucose, but a harmful interaction with glimepiride has not been demonstrated in the sources checked. Findings vary by product and study. Discuss supplement use with your diabetes clinician; neither blanket avoidance nor a protective spacing interval is established.
- Exact scope
- Momordica charantia fruit preparations with oral glimepiride. Prediabetes studies without medicines and specified extracts are not equivalent to all seed, juice or food products. with Oral glimepiride tablets for type 2 diabetes.
- Medication form and route
- oral
What remains uncertain
- No quantified exact-pair risk or protective spacing interval is established. Original-source access and population limitations are documented individually.
Factors that may matter: Exact preparation and amount; Other glucose-lowering treatment; Meal schedule, kidney function and glucose readings.
Read the supporting source summaries
Source 1: Current U.S. regulatory product labeling
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults with type 2 diabetes using oral glimepiride.
Glimepiride can cause severe hypoglycemia. Nicotinic acid is listed among agents that may reduce glucose control. The specified four-hour-before instruction applies to colesevelam.
How this applies: Exact medication labeling provides administration and monitoring context, not proof of untested supplement effects.
The label does not establish every botanical interaction. Colesevelam instructions cannot be transferred to charcoal, glucomannan or other supplements.
Source 2: Original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40 adults with type 2 diabetes on standard treatment.
No significant benefit in HbA1c, fasting glucose or several other metabolic outcomes; a few mild adverse events occurred.
How this applies: Contrary evidence limits a blanket statement that this supplement always lowers glucose.
Small trial; original abstract does not identify glimepiride co-use. Product findings are not proof about every preparation.
Source 3: Original human clinical study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 76 participants with prediabetes randomized; glucose-affecting medicines excluded.
Some post-challenge glucose and glucagon measures improved.
How this applies: Potential glucose activity is indirect for medication-associated hypoglycemia.
Selected untreated population, product-specific findings and multiple glucose measures. This was not a glimepiride combination trial.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Initial source-checked research draft. Exact preparations, contrary findings and study limitations documented; clinical review not recorded. | |
| Research summary published |
Article revision: bc1846a92e632acc
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.